Posts tagged ‘XL-184’
May 24th, 2011
The countdown is underway for the 2011 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-7th. Over 30,000 attendees are expected and more than 4,000 abstracts will be presented.
What’s hot at the meeting is what everyone is asking? Sally Church is preparing a video blog (vlog) with her thoughts that will be posted on Pharma Strategy Blog soon.
In the meantime, two new products to watch out for are:
Cabozantinib (XL184). This new product from Exelixis may have potential in advanced prostate cancer with phase II data showing a dramatic effect on bone metastases, making it a potential competitor to denosumab. You can read more about the ASCO data on Biotech Strategy Blog.
Olaparib. Just when we thought that PARP inhibitors were ineffective after the failure of iniparib in breast cancer, there’s dramatic data at ASCO showing AstraZeneca’s olaparib prolongs remission in serious ovarian cancer. You can read more on Pharma Strategy Blog.
The focus of ASCO 2011 is “Patients, Pathways, Progress”. We’ll be writing more about the meeting over the next few weeks, so do check back for more details.
May 18th, 2011
The data from this study was presented in Tuesday’s plenary session by Dr Tim Wilt, a Professor at the University of Minnesota, and was to many attendees, the highlight of the meeting.
The trial results showed for the first time that radical prostatectomy (RP) is no better than watchful waiting in men with early stage prostate cancer using evidence based medicine.
This groundbreaking research is likely to have a major impact on urology practice in the United States.
Pieter Droppert wrote about the PIVOT results on Biotech Strategy Blog. Scott Hensley on NPR’s Health Blog, “Shots” references Pieter’s post, and has an interview with Dr Wilt that is also well worth reading.
Also presented at AUA in Tuesday’s plenary session were the results from:
This study looked at castrate resistant prostate cancer patients at high risk of development of bone metastasis.
Sally Church on Pharma Strategy Blog discusses the results presented by Dr Matthew Smith at AUA. Denosumab was shown to increase bone metastasis-free survival and delayed time to first bone metastasis, but did not increase overall survival (OS).
Both Sally Church and Pieter Droppert also wrote additional blog posts from the meeting. On Biotech Strategy Blog, Pieter wrote about data that showed:
He also wrote about:
Some of the new products mentioned in Pieter’s post include alpharadin, XL-184 (cabozantinib), Prostvac-VF, BPX-101 and ipilimumab. You can read more on Biotech Strategy Blog.
Meanwhile on Pharma Strategy Blog, Sally Church continued one of her themes of how social media is impacting medical conferences by reviewing:
Sally also recorded a video blog post (vlog) from AUA that highlighted some of the exciting developments in basic biology and how this may lead to new Prostate Cancer treatments in the future. Click here to watch this.
If you were unable to attend the meeting, Sally aggregated the #AUA2011 tweets.
Selecting what to write about on a blog is subjective, so the above posts are not intended to provide comprehensive meeting or conference coverage, only a few highlights of what was presented at the highly informative and educational AUA annual meeting.
If you are interested in a more comprehensive report on the Prostate Cancer Market and the emerging new products in development, please do not hesitate to contact us.